DMD Large equally mixed donor pool

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blaisdell, J.
Right arrow Articles by Bai, S. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blaisdell, J.
Right arrow Articles by Bai, S. A.

Vol. 26, Issue 3, 278-283, March 1998

Isolation of a New Canine Cytochrome P450 CDNA from the Cytochrome P450 2C Subfamily (CYP2C41) and Evidence for Polymorphic Differences in Its Expression

Joyce Blaisdell, Joyce A. Goldstein, and Stephen A. Bai

National Institutes of Environmental Health Sciences (J.B., J.A.G.) and the Department of Anatomy, Physiological Sciences, and Radiology, College of Veterinary Medicine, North Carolina State University (S.A.B.)

Two members of the canine cytochrome P4502C subfamily [CYP2C21 and CYP2C41 (sequence has been submitted to Genbank with accession number AF016248)] were cloned from three beagle liver cDNA libraries. The two canine CYP2C cDNAs exhibited 70% nucleotide and amino acid identity as well as 74-83% nucleotide and 67-76% amino acid identity with the human CYP2Cs. Canine CYP2C41 is more homologous to the human CYP2Cs than CYP2C21. The two canine CYP2C cDNAs exhibited a slightly lower nucleotide and amino acid identity (66-77%) with the rat P450CYPs, 2C11 and 2C12. Reverse transcription-polymerase chain reaction-based restriction enzyme tests for CYP2C21 and 2C41 mRNAs as well as polymerase chain reaction-based tests for genomic DNA were developed. CYP2C21 cDNA was present in the livers of all dogs tested (N = 9), but CYP2C41 was present in only 1 of the 9 (11%). Genomic tests found that the gene coding for CYP2C21 was also present in all dogs tested (N = 25), of which 15 were beagles and 10 mixed breeds. In contrast, the gene coding for CYP2C41 was present in only 16% (4 out of 25) of the dogs. An even distribution of the CYP2C41 gene was found between the sexes and between beagles and mixed breeds. This unique polymorphism in the canine CYP2C subfamily may be a source of variability in the metabolic clearance in dogs of xenobiotics that are metabolized by the cytochrome P450 2C subfamily of enzymes.

Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
M. Mise, T. Hashizume, and S. Komuro
Characterization of Substrate Specificity of Dog CYP1A2 Using CYP1A2-Deficient and Wild-Type Dog Liver Microsomes
Drug Metab. Dispos., September 1, 2008; 36(9): 1903 - 1908.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
D. Aidasani, M. J. Zaya, P. B. Malpas, and C. W. Locuson
In Vitro Drug-Drug Interaction Screens for Canine Veterinary Medicines: Evaluation of Cytochrome P450 Reversible Inhibition
Drug Metab. Dispos., August 1, 2008; 36(8): 1512 - 1518.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
D. Tenmizu, K. Noguchi, H. Kamimura, H. Ohtani, and Y. Sawada
THE CANINE CYP1A2 DEFICIENCY POLYMORPHISM DRAMATICALLY AFFECTS THE PHARMACOKINETICS OF 4-CYCLOHEXYL-1-ETHYL-7-METHYLPYRIDO[2,3-D]-PYRIMIDINE-2-(1H)-ONE (YM-64227), A PHOSPHODIESTERASE TYPE 4 INHIBITOR
Drug Metab. Dispos., May 1, 2006; 34(5): 800 - 806.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
P. Lu, S. B. Singh, B. A. Carr, Y. Fang, C. D. Xiang, T. H. Rushmore, A. D. Rodrigues, and M. Shou
Selective Inhibition of Dog Hepatic CYP2B11 and CYP3A12
J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 518 - 528.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. Mise, S. Yadera, M. Matsuda, T. Hashizume, S. Matsumoto, Y. Terauchi, and T. Fujii
POLYMORPHIC EXPRESSION OF CYP1A2 LEADING TO INTERINDIVIDUAL VARIABILITY IN METABOLISM OF A NOVEL BENZODIAZEPINE RECEPTOR PARTIAL INVERSE AGONIST IN DOGS
Drug Metab. Dispos., February 1, 2004; 32(2): 240 - 245.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. Shou, R. Norcross, G. Sandig, P. Lu, Y. Li, Y. Lin, Q. Mei, A. D. Rodrigues, and T. H. Rushmore
SUBSTRATE SPECIFICITY AND KINETIC PROPERTIES OF SEVEN HETEROLOGOUSLY EXPRESSED DOG CYTOCHROMES P450
Drug Metab. Dispos., September 1, 2003; 31(9): 1161 - 1169.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
J. Tibbitts
Issues Related to the Use of Canines in Toxicologic Pathology--Issues With Pharmacokinetics and Metabolism
Toxicol Pathol, January 1, 2003; 31(1_suppl): 17 - 24.
[Abstract] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. M. Lankford, S. A. Bai, and J. A. Goldstein
Cloning of Canine Cytochrome P450 2E1 cDNA: Identification and Characterization of Two Variant Alleles
Drug Metab. Dispos., August 1, 2000; 28(8): 981 - 986.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
S. K. Paulson, L. Engel, B. Reitz, S. Bolten, E. G. Burton, T. J. Maziasz, B. Yan, and G. L. Schoenhard
Evidence for Polymorphism in the Canine Metabolism of the Cyclooxygenase 2 Inhibitor, Celecoxib
Drug Metab. Dispos., October 1, 1999; 27(10): 1133 - 1142.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics.